Long-term Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls open 6-year follow-up of an initial observer-blinded, randomized trial

Pediatric Infectious Disease Journal

Volumn 33, Issue 12, 2014, Pages 1255-1261

  Schwarz, Tino F ^a   Huang, Li Min ^b   Lin, Tzou Yien ^c   Wittermann, Christoph ^d   Panzer, Falko ^e   Valencia, Alejandra ^f   Suryakiran, Pemmaraju V ^g   Lin, Lan ^h   Descamps, Dominique ⁱ  

^a Central Laboratory and Vaccination Centre   (Germany)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d Praxis für Kinder und Jugendmedizin Weilheim iOB ^*  (Germany)

^e Pädiatrische Infektiologie und Pneumologie Universitätsklinik für Kinder und Jugendmedizin Mannheim   (Germany)

^f HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^g Glaxo SmithKline Biologicals   (India)

^h XPePharma and Science   (Belgium)

ⁱ GSK   (Belgium)

Author keywords

Adolescent; HPV 16 18 AS04 adjuvanted vaccine; Human papillomavirus; Immunogenicity; Persistence

Indexed keywords

WART VIRUS VACCINE; ALUMINUM HYDROXIDE; ASO4 MIXTURE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; IMMUNOLOGICAL ADJUVANT; LIPID A; VIRUS ANTIBODY;

ABDOMINAL PAIN; ANTIBODY RESPONSE; ANTIBODY TITER; AORTA RUPTURE; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; MAJOR CLINICAL STUDY; OVARY CYST; PAPILLOMAVIRUS INFECTION; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SCHOOL CHILD; SPONTANEOUS ABORTION; TREATMENT OUTCOME; VACCINATION; ADOLESCENT; ADULT; ANALOGS AND DERIVATIVES; BLOOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; NEWBORN; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; SINGLE BLIND PROCEDURE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; ANTIBODIES, VIRAL; CHILD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; LIPID A; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREGNANCY; SINGLE-BLIND METHOD; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84926192630     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000460     Document Type: Article

References (37)

1. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
3. de Sanjose S, Quint WG, Alemany L, et al.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056.
4. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available at: http://globocan. iarc.fr. Accessed September 10, 2013.
5. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191:182-192.
6. Castellsagué X, Schneider A, Kaufmann AM, et al. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol. 2009;115(3 suppl):S15-S23.
7. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG. 2002;109:96-98.
8. Coupé VM, Berkhof J, Bulkmans NW, et al. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer. 2008;98:646-651.
9. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819.
10. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119:2677-2684.
11. Moscicki AB. HPV infections in adolescents. Dis Markers. 2007;23:229-234.
12. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157:218-226.
13. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine. 2010;28:6247-6255.
14. Harper DM, Franco EL, Wheeler C, et al.; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765.
15. Harper DM, Franco EL, Wheeler CM, et al.; HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
16. Harper DM. Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol. 2008;110(3 suppl 1):S11-S17.
17. Lehtinen M, Paavonen J, Wheeler CM, et al.; HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89-99.
18. Naud P, Roteli-Martins CM, De Carvalho N, Teixeira J, et al. HPV-16/18 vaccine: sustained immunogenicity and efficacy up to 9.4 years. In: 27th International Papillomavirus Conference and Clinical Workshop, September 17-22, 2011. Berlin, Germany,.
19. Paavonen J, Jenkins D, Bosch FX, et al.; HPV PATRICIA Study Group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-2170.
20. Paavonen J, Naud P, Salmerón J, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-314.
21. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-1985.
22. Roteli-Martins CM, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother. 2012;8:390-397.
23. Szarewski A, Poppe WA, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012;131:106-116.
24. David MP, Van Herck K, Hardt K, et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol. 2009;115(3 suppl):S1-S6.
25. Pedersen C, Petaja T, Strauss G, et al.; HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564-571.
26. Petäjä T, Pedersen C, Poder A, et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer. 2011;129:2147-2157.
27. Medina DM, Valencia A, de Velasquez A, et al.; HPV-013 Study Group. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health. 2010;46:414-421.
28. Schwarz TF, Huang LM, Medina DM, et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolesc Health. 2012;50:187-194.
29. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24:5937-5949.
30. Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007;25:4324-4333.
31. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-587.
32. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911-1919.
33. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis. 2002;186:737-742.
34. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev. 2004;13:324-327.
35. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis. 2002;35:1368-1375.
36. Kumar R, Burns EA. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev Vaccines. 2008;7:467-479.
37. Castellsagué X for the PATRICIA Study Group. Relationship between the risk of new HPV-16 infection and naturally-acquired type-specific antibody titres. In: European Research Organization on Genital Infection and Neoplasia, July 8-11, 2012. Prague, Czech Republic.